222 related articles for article (PubMed ID: 37832567)
1. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD
Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567
[TBL] [Abstract][Full Text] [Related]
2. sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies.
Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos R
medRxiv; 2023 Apr; ():. PubMed ID: 37066200
[TBL] [Abstract][Full Text] [Related]
3. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
[TBL] [Abstract][Full Text] [Related]
5. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
[TBL] [Abstract][Full Text] [Related]
6. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
[TBL] [Abstract][Full Text] [Related]
7. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
[TBL] [Abstract][Full Text] [Related]
8. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
10. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
11. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
[TBL] [Abstract][Full Text] [Related]
12. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
Armenia D; Santoro MM; Charpentier C; Bertoli A; Forbici F; Calvez V; Descamps D; Ceccherini-Silberstein F; Marcelin AG; Flandre P
J Antimicrob Chemother; 2023 Jun; 78(6):1415-1422. PubMed ID: 37258034
[TBL] [Abstract][Full Text] [Related]
14. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338
[No Abstract] [Full Text] [Related]
15. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the genetic mechanisms of dolutegravir resistance.
Rhee SY; Grant PM; Tzou PL; Barrow G; Harrigan PR; Ioannidis JPA; Shafer RW
J Antimicrob Chemother; 2019 Nov; 74(11):3135-3149. PubMed ID: 31280314
[TBL] [Abstract][Full Text] [Related]
18. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
19. Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.
Arimide DA; Szojka ZI; Zealiyas K; Gebreegziabxier A; Adugna F; Sasinovich S; Björkman P; Medstrand P
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458459
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT
AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
